Skip to content
Search

Latest Stories

Boots pharmacist claim of harassment related to race

A recent employment tribunal has affirmed a pharmacist's allegation of racial harassment during his employment at Boots, especifically citing an incident that occurred in July 2020

An employment tribunal has ruled in favour of a pharmacist, Samson Famojuro, who claimed he faced racial harassment during his tenure at Boots pharmacy.


The decision comes after a five-day hearing earlier this year, where the tribunal found that Famojuro, of Nigerian origin and working as the Responsible Pharmacist at Boots’ Silva Island Way branch in Wickford, Essex, was subjected to race-related treatment by pre-registration pharmacy technician Emma Walker in July 2020.

The tribunal criticized the "inconsistent and untruthful evidence" presented by Walker and pharmacy adviser Nicole Daley during the proceedings.

It suggested that their "repeated allegations of aggression" against Famojuro could lead to the conclusion that they were stereotyping him "as an aggressive black man when all he was doing was seeking to assert his authority."

While the tribunal dismissed some claims of harassment and direct race discrimination, it upheld Famojuro's claim for unfair constructive dismissal.

The incident occurred on July 18, 2020, when Walker and Daley, both in junior positions to Famojuro, allegedly undermined his authority as the Responsible Pharmacist.

Famojuro requested assistance with filing bagged items and prescriptions, but tensions arose when Daley refused, insisting filing was solely the responsibility of the pharmacist. Further disputes emerged when Famojuro realized labelling errors on bags, and Daley refused to correct them.

Subsequent events, including handling a prescription for an Asian patient and a confrontation in the staff room, led to Famojuro feeling undermined and unsafe.

The tribunal noted inconsistencies and untruths in Walker and Daley's evidence, highlighting their cooperation on statements and a tendency to make fresh allegations when flaws were pointed out.

The pharmacist was eventually asked to leave by Walker, supported by branch manager Amy Munson, who reportedly did not investigate the situation thoroughly.

The tribunal concluded that Walker, Daley, and Munson "escalated the situation" to the point where they turned against Famojuro.

It expressed concern over the "inconsistent and untruthful evidence," suggesting racial stereotyping by Walker and Daley. Boots' investigation into the allegations was criticized for not adequately exploring whether race played a role.

Boots responded to the ruling, stating, "At Boots, we stand firmly against workplace harassment of any kind. We are reviewing the court’s findings and will reflect and take action on any learnings."

The tribunal's decision sheds light on the importance of thorough workplace investigations and the potential consequences of racial stereotyping in professional settings.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less